Post MI Clinical Trial
Official title:
Kardia - A Smartphone-based Care Model for Outpatient Cardiac Rehabilitation
NCT number | NCT03415841 |
Other study ID # | Kardia |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 1, 2018 |
Est. completion date | March 31, 2020 |
This study hopes to target the remaining 80% of low risk post-myocardial infarction patients
who have refused uptake the traditional cardiac rehabilitation program In Changi General
Hospital. This is a 6-week home-based Cardiac rehabilitation program enabling patients to
track their blood pressure, physical activity and medicine compliance through a mobile
application. Each patient in the intervention arm is provided with a blood pressure monitor,
activity tracker and a single lead ECG monitor. The data from these devices would be
automatically synced by a mobile application and uploaded to a confidential web portal which
is only accessible by physician care-givers. The application also provides educational
content/tasks, appropriate reminders for taking medications and daily goals on activity
targets set by the care provider. This would help to engage the patients to enable
behavioural change and improve compliance to mediation and activity recommendations.
In general, 50 patients who are randomized to the intervention group (mHealth) will be
enabled with remote monitoring devices (ECG, Blood Pressure, Activity tracker) and "Kardia"
mobile application, for home-based rehabilitation program followed by review in the
outpatient Cardiology clinics. The control group (50 subjects) will just be monitored at
fixed intervals in the outpatient Cardiology clinics. Fu AT 3-4 months & 9-12 months.
Subjects will be advised to commence the exercise program 2 weeks after the myocardial
infarction. Block randomization using sequentially numbered sealed envelopes would be used to
assign subjects to the intervention or control arms. The primary outcome measure is
compliance and adherence to the "Kardia" program. Other endpoints include 6MWT, patient
wellbeing and behaviour (e.g. dietary habits, stress levels, physical activity) assessed
using questionnaires, major adverse cardiovascular events (MACE), modification of
cardiovascular risk profiles (i.e. LDL, BP, BMI, HbA1c, etc) and medicine compliance.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | March 31, 2020 |
Est. primary completion date | November 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Age 21-85 years - Willing and able to provide informed consent - New onset of Post ST elevation and non-ST elevation myocardial infarction/staged PCI/acute coronary syndrome/unstable angina - Own and able to operate App on smartphone Exclusion Criteria: - History of ventricular fibrillation not in the setting of acute myocardial infarction - Documented sustained ventricular or supraventricular arrhythmia - Unstable angina - Awaiting staged revascularization - Inability to perform 6MWT |
Country | Name | City | State |
---|---|---|---|
Singapore | Changi General Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
Changi General Hospital | Biofourmis |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compliance and adherence to the "Kardia" program | Compliance to smart phone based cardiac rehabilitation program - Uploading of completed data (BP, activity) to web portal. Compliance is defined as taking at least 1 BP per day and wearing the Biovotion for >10 hours per day. (90% compliance in intervention group would be considered acceptable) |
9 months | |
Secondary | Improvement in 6MWT | 6MWT at baseline (within 2 weeks upon discharge) months 3 (+/- 2 months) and 9 (+/- 3 months) will be analysed and compared | 9 Months | |
Secondary | Major Adverse Cardiovascular Events (MACE) and Hospitalizations | Reduction in MACE and Hospitalization | 12 months | |
Secondary | Improvement in quality of life | EQ5D questionaire | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02070679 -
Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography
|
Phase 3 |